Takeda hands regulatory affairs work to PRA in new deal

By Gareth Macdonald

- Last updated on GMT

iStock/BernardaSv
iStock/BernardaSv
Takeda will hand regulatory affairs work to PRA Health Sciences under the clinical development services deal announced last night.

The agreement – financial terms of which were not disclosed – will see PRA manage clinical trials of all drugs in Takeda’s pipeline and see around 300 of the Japanese drug manufacturer’s employees join the contract research organization (CRO).

PRA spokeswoman Christine Rogers told us a wide range of clinical development activities have been handed over to the firm adding that “some regulatory affairs will be included, along with all other development-related functions.” She declined to provide additional details.

The firms said the deal will add flexibility and allow Takeda to reduce its costs.

R&D rejig

Takeda has been reorganizing its R&D operations for the past few years.

In July​ the firm said it would accelerate the process by concentrating its drug development efforts in the US and Japan and focusing on drugs for cancer, gastroenterology, central nervous system disorders and vaccines.

Takeda has signed “strategic” deals with CRO before. In 2011, for example it hired Covance and Quintiles.

Related news

Related products

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

The Complete Guide to eRegulatory and eSource

The Complete Guide to eRegulatory and eSource

Content provided by Florence Healthcare | 01-Apr-2023 | Insight Guide

Shifting to eRegulatory and eSource workflows is a requirement for clinical trial sites to continue to scale and grow their studies. This guide is designed...

Follow us

Products

View more

Webinars